Andrew A. Nierenberg

Andrew A. Nierenberg

Auto-generated profile, based on publicly available information

Andrew A. Nierenberg

Bipolar Clinic and Research Program Massachusetts General Hospital Boston MA USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2009 in Psychological Medicine
Verified
Journal Article
Closed access
PDF file
ANA. A. Nierenberg
A. A. Nierenberg
MHM. M. Husain
M. M. Husain
MTM. H. Trivedi
M. H. Trivedi
MFM. Fava
M. Fava
DWD. Warden
D. Warden
ARA. J. Rush
A. J. Rush
Background: Many patients with major depressive disorder (MDD) who experience full symptomatic remission after antidepressant treatment still have residual depressive symptoms. We describe the types and frequency of residual depressive symptoms and their relationship to subsequent depressive relapse after treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.Method: Participants in primary (n=18) and psychiatric (n=23) practice settings were openly treated with citalopram using measurement-based care for up to 14 weeks and follow-up for up to 1 year. We assessed 943 (32.8% of 2876) participants who met criteria for remission to determine the proportions with individual residual symptoms and any of the nine DSM-IV criterion symptom domains to define a major depressive episode. At each visit, the 16-item Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR16) and the self-report Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) scale were used to assessed depressive symptoms and side-effects respectively.Results: More than 90% of remitters had at least one residual depressive symptom (median=3). The most common were weight increase (71.3%) and mid-nocturnal insomnia (54.9%). The most common residual symptom domains were sleep disturbance (71.7%) and appetite/weight disturbance (35.9%). Those who remitted before 6 weeks had fewer residual symptoms at study exit than did later remitters. Residual sleep disturbance did not predict relapse during follow-up. Having a greater number of residual symptom domains was associated with a higher probability of relapse.Conclusions: Patients with remission of MDD after treatment with citalopram continue to experience selected residual depressive symptoms, which increase the risk of relapse.

1 June 2005 in Biological Psychiatry
Verified
Journal Article
Closed access
ANAndrew A. Nierenberg
Andrew A. Nierenberg
SMSachiko Miyahara
Sachiko Miyahara
TSTom Spencer
Tom Spencer
SWStephen R. Wisniewski
Stephen R. Wisniewski
MOMichael W. Otto
Michael W. Otto
GSGary S. Sachs
Gary S. Sachs

1 February 2006 in American Journal of Psychiatry
Verified
Journal Article
Closed access
ANAndrew A Nierenberg
Andrew A Nierenberg
MOMichael J Ostacher
Michael J Ostacher
JCJoseph R Calabrese
Joseph R Calabrese
TKTerence A Ketter
Terence A Ketter
LMLauren B Marangell
Lauren B Marangell
GSGary S Sachs
Gary S Sachs

1 September 2000 in American Journal of Psychiatry
Verified
Journal Article
Closed access
ANAndrew A. Nierenberg
Andrew A. Nierenberg
AFAmy H. Farabaugh
Amy H. Farabaugh
JAJonathan E. Alpert
Jonathan E. Alpert
JGJohanna Gordon
Johanna Gordon
JWJohn J. Worthington
John J. Worthington
MFMaurizio Fava
Maurizio Fava


27 March 2017 in International Journal of Bipolar Disorders
Verified
Journal Article
Open access
PDF file
LSLouisa G. Sylvia
Louisa G. Sylvia
RMRebecca E. Montana
Rebecca E. Montana
TDThilo Deckersbach
Thilo Deckersbach
MTMichael E. Thase
Michael E. Thase
MTMauricio Tohen
Mauricio Tohen
ANAndrew A. Nierenberg
Andrew A. Nierenberg
Background: This study explores the association of demographic and clinical features with quality of life and functioning in individuals with bipolar disorder. Methods: Adult participants (N = 482) with bipolar I or II disorder were enrolled in a comparative effectiveness study across eleven study sites and completed baseline measures of medical and psychiatric history, current mood, quality of life, and functioning. Participants with at least mildly depressive or manic/hypomanic symptomatic severity were randomized to receive lithium or quetiapine in addition to adjunctive personalized treatment for 6 months. Results: Participants with more severe depressive and irritability symptoms had lower quality of life and higher functional impairment. All psychiatric comorbid conditions except substance use disorder were associated with worse quality of life. On average, females had lower quality of life than males. Patients who were married, living as married, divorced, or separated had worse functional impairment compared with patients who were single or never married. A composite score of social disadvantage was associated with worse functioning and marginally associated with worse quality of life. Symptom severity did not moderate the effect of social disadvantage on quality of life or functioning. Conclusions: Our findings highlight that depression, irritability, and psychiatric comorbid conditions negatively impact quality of life and functioning in bipolar disorder. The study suggests that individuals with social disadvantage are at risk for functional impairment. Trial Registration This study is registered with ClinicalTrials.gov. Identification number: NCT01331304